Progression Biobank of Achalasia and autoimmune gastritis

Progression Biobank of Achalasia and autoimmune gastritis - PROBAAI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49853

Enrollment

300

Registered

2021-04-30

Start date

2020-12-31

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune metaplastic atrophic gastritis gastrointestinal tumors

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Diagnosis of autoimmune gastritis or achalasia

Exclusion criteria

Exclusion criteria: History of surgery in the upper gastrointestinal tract, including the stomach or esophagus. Subjects with portal hypertension.

Design outcomes

Primary

Measure	Time frame
1. Risk of malignant progression in AIG and achalasia. 2. Infiltrating immune cells in biopsy from patients with AIG and achalasia. 3. Autoantibodies in the serum from AIG and achalasia patients. 4. The prevalence of HSV-1 and -2, human papillomavirus (HPV), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV) and H. pylori infection in AIG and achalasia patients. 5. HLA genotyping data in AIG and achalasia patients.	—

Measure

Time frame

1. Risk of malignant progression in AIG and achalasia. 2. Infiltrating immune cells in biopsy from patients with AIG and achalasia. 3. Autoantibodies in the serum from AIG and achalasia patients. 4. The prevalence of HSV-1 and -2, human papillomavirus (HPV), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV) and H. pylori infection in AIG and achalasia patients. 5. HLA genotyping data in AIG and achalasia patients.

—

Secondary

Measure	Time frame
1. Investigate whether the diagnosis of achalasia can be performed by immunofluorescence imaging of serum on rat tissues (as is now routinely performed for AIG). 2. Attempt to create an organoid biobank from freshly collected gastric and esophagus biopsies to set up a preclinical model to identify the specific autoantibody in achalasia and AIG. 3. To evaluate the microbiota composition in the esophagus and gastric mucosa.	—

Measure

Time frame

1. Investigate whether the diagnosis of achalasia can be performed by immunofluorescence imaging of serum on rat tissues (as is now routinely performed for AIG). 2. Attempt to create an organoid biobank from freshly collected gastric and esophagus biopsies to set up a preclinical model to identify the specific autoantibody in achalasia and AIG. 3. To evaluate the microbiota composition in the esophagus and gastric mucosa.

—

Countries

Netherlands

Outcome results